Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway

Leukemia Research

Volumn 37, Issue 12, 2013, Pages 1719-1725

  Zhang, Xiao Hui ^a   Feng, Ru ^b   Lv, Meng ^a   Jiang, Qian ^a   Zhu, Hong Hu ^a   Qing, Ya Zhen ^a   Bao, Jia Ling ^c   Huang, Xiao Jun ^a   Zheng, X Long ^c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING HOSPITAL   (China)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Apoptosis; Arsenic trioxide; P53 and CLL; Survivin; WSU CLL

Indexed keywords

ARSENIC TRIOXIDE; PROTEIN P53; SMALL INTERFERING RNA; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84888128147     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.019     Document Type: Article

References (41)

1. Caligaris-Cappio F., Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999, 17:399-408.
2. Li H.M., Long Y., Qing C., Yu M., Li Z.H., Zhang X.M., et al. Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. Oncol Res 2011, 19:149-163.
3. Jutooru I., Chadalapaka G., Sreevalsan S., Lei P., Barhoumi R., Burghardt R., et al. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res 2010, 316:2174-2188.
4. Stevens J.J., Graham-Evans B., Walker A.M., Armstead B., Tchounwou P.B. Cytotoxic effect of arsenic trioxide in adenocarcinoma colorectal cancer (HT-29) cells. Met Ions Biol Med 2008, 10:458-462.
5. Pettersson H.M., Pietras A., Munksgaard Persson M., Karlsson J., Johansson L., Shoshan M.C., et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther 2009, 8:160-170.
6. Vey N., Bosly A., Guerci A., Feremans W., Dombret H., Dreyfus F., et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006, 24:2465-2471.
7. Merkel O., Heyder C., Asslaber D., Hamacher F., Tinhofer I., Holler C., et al. Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med (Berl) 2008, 86:541-552.
8. Bairey O., Vanichkin A., Shpilberg O. Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol 2010, 32:e77-e85.
9. Redondo-Munoz J., Escobar-Diaz E., Hernandez Del Cerro M., Pandiella A., Terol M.J., Garcia-Marco J.A., et al. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 2010, 16:4382-4391.
10. Goussetis D.J., Platanias L.C. Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia. Clin Cancer Res 2010, 16:4311-4312.
11. Biswas S., Zhao X., Mone A.P., Mo X., Vargo M., Jarjoura D., et al. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro. Leuk Res 2010, 34:925-931.
12. Sisson T.H., Maher T.M., Ajayi I.O., King J.E., Higgins P.D., Booth A.J., et al. Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol 2012, 3:657-664.
13. Feng R., Zhou S., Liu Y., Song D., Luan Z., Dai X., et al. Sox2 protects neural stem cells from apoptosis via up-regulating survivin expression. Biochem J 2013, 450(3):459-468.
14. Smolewski P., Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med 2011, 11:633-649.
15. Grzybowska-Izydorczyk O., Cebula B., Robak T., Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 2010, 46:800-810.
16. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009, 35:553-562.
17. Ghaffari S.H., Momeny M., Bashash D., Mirzaei R., Ghavamzadeh A., Alimoghaddam K. Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkbeta-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology 2012, 17:198-206.
18. Chiu H.W., Ho Y.S., Wang Y.J. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin. J Mol Med (Berl) 2011, 89:927-941.
19. Kircelli F., Akay C., Gazitt Y. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53. Int J Oncol 2007, 30:993-1001.
20. Keim A., Rossler O.G., Rothhaar T.L., Thiel G. Arsenite-induced apoptosis of human neuroblastoma cells requires p53 but occurs independently of c-Jun. Neuroscience 2012, 206:25-38.
21. Ho S.Y., Chen W.C., Chiu H.W., Lai C.S., Guo H.R., Wang Y.J. Combination treatment with arsenic trioxide and irradiation enhances apoptotic effects in U937 cells through increased mitotic arrest and ROS generation. Chem Biol Interact 2009, 179:304-313.
22. Zhao S., Zhang J., Zhang X., Dong X., Sun X. Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep 2008, 35:421-429.
23. Mathieu J., Besancon F. Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. Int J Cancer 2006, 119:1723-1727.
24. Ling X., Cao S., Cheng Q., Keefe J.T., Rustum Y.M., Li F. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS ONE 2012, 7:e45571.
25. Guo L., Tang M., Yang L., Xiao L., Bode A.M., Li L., et al. Epstein-Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma. Int J Mol Med 2012, 29:574-580.
26. Tyner J.W., Jemal A.M., Thayer M., Druker B.J., Chang B.H. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia 2012, 26:623-632.
27. Bongiovanni L., Mazzocchetti F., Malatesta D., Romanucci M., Ciccarelli A., Buracco P., et al. Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, beta-catenin, p53, caspase 3) in canine appendicular osteosarcoma. BMC Vet Res 2012, 8:78.
28. Shao Y., Liu Y., Shao C., Hu J., Li X., Li F., et al. Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. Cancer Gene Ther 2010, 17:844-854.
29. Nabilsi N.H., Broaddus R.R., Loose D.S. DNA methylation inhibits p53-mediated survivin repression. Oncogene 2009, 28:2046-2050.
30. Wall N.R., Beck F.W., Al-Katib A.M., Mohammad R.M. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. J Drug Target 2001, 9:329-339.
31. Moon E.Y., Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 2002, 62:5711-5719.
32. Mohammad R.M., Mohamed A.N., Hamdan M.Y., Vo T., Chen B., Katato K., et al. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996, 10:130-137.
33. Jin H.O., Yoon S.I., Seo S.K., Lee H.C., Woo S.H., Yoo D.H., et al. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 2006, 72:1228-1236.
34. Li Y., Jiang R., Zhao Y., Xu Y., Ling M., Pang Y., et al. Opposed arsenite-mediated regulation of p53-survivin is involved in neoplastic transformation, DNA damage, or apoptosis in human keratinocytes. Toxicology 2012, 300:121-131.
35. Stevens J.J., Graham B., Walker A.M., Tchounwou P.B., Rogers C. The effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cells. Int J Environ Res Public Health 2010, 7:2018-2032.
36. Walker A.M., Stevens J.J., Ndebele K., Tchounwou P.B. Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells. Int J Environ Res Public Health 2010, 7:1996-2007.
37. Zhu X.H., Shen Y.L., Jing Y.K., Cai X., Jia P.M., Huang Y., et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999, 91:772-778.
38. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
39. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277:3247-3257.
40. Wang K., Brems J.J., Gamelli R.L., Holterman A.X. Survivin signaling is regulated through nuclear factor-kappa B pathway during glycochenodeoxycholate-induced hepatocyte apoptosis. Biochim Biophys Acta 2010, 1803:1368-1375.
41. Raj D., Liu T., Samadashwily G., Li F., Grossman D. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 2008, 29:194-201.